Related Experiment Video
Updated: Aug 19, 2026

Veno-Venous Extracorporeal Membrane Oxygenation in a Mouse
Published on: October 24, 2018
Nesiritide during extracorporeal membrane oxygenation
Todd Smith1, David A Rosen, Pierantonio Russo
1Department of Anesthesiology, University of Missouri, Columbia, MO 65212, USA.
Abstract:
Nesiritide is a recombinant formulation of B-type natriuretic peptide (BNP). Preliminary experience in the adult population has shown nesiritide to be an effective agent in the treatment of decompensated congestive heart failure (CHF) in adults. Given its physiological effects, it may be an effective agent in other clinical scenarios. We report the use of nesiritide in two infants during extracorporeal membrane oxygenation (ECMO). In one patient, nesiritide in doses up to 0.09 microg.kg(-1).min(-1) were used to control mean arterial pressure while in the other patient, doses of 0.01-0.03 microg.kg(-1).min(-1) were used to augment urine output. The potential applications of nesiritide and dosing regimens for this agent in the ECMO population are discussed.
Related Concept Videos
Extracorporeal Removal of Drugs: Continuous Renal Replacement Therapy
Acute Respiratory Failure-V
Ensure that patients are monitored continuously for their response to therapy, including changes in...
Acute Respiratory Failure-IV
Continuous Renal Replacement Therapy
Mechanical Ventilation III: Noninvasive Ventilation
Noninvasive Positive-Pressure Ventilation (NIPPV)
Cardiopulmonary Resuscitation IV: Pharmacological Management
